Actuate Therapeutics, Inc. Common stock (ACTU)
PHARMACEUTICAL PREPARATIONS
Actuate Therapeutics, Inc. Common stock (ACTU) is listed on Nasdaq, where it has traded since August 13, 2024.
- Listed On
- Nasdaq
- Listed Since
- August 13, 2024
- Employees
- 12
- Market Cap
- $19M
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 61 institutions reported holding ACTU, with 13.5 million shares worth $20.6 million in aggregate. The largest reported holder was Bios Capital Management, with 10.0 million shares worth $15.4 million. Of the 5 largest holders listed below, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Bios Capital Management | 10,049,996 | $15M | Unchanged |
| Voss Capital | 1,725,000 | $3M | Unchanged |
| Vanguard | 453,032 | $693K | Reduced 3.24% |
| AQR Capital Management | 127,493 | $195K | Added 370.3% |
| Geode Capital Management | 112,554 | $172K | Reduced 50.71% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ACTU?
Actuate Therapeutics, Inc. Common stock (ACTU) is listed on Nasdaq, where it has traded since August 13, 2024.
Who are the largest institutional holders of ACTU?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ACTU were Bios Capital Management, Voss Capital and Vanguard.
How many institutions own ACTU?
61 institutions reported a position in ACTU for the quarter ended June 30, 2026, worth $20.6 million in total.
Did institutions buy or sell ACTU last quarter?
Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ACTU.
Every reported institutional holder, plus insider and congressional trades in ACTU, on SentiSense.